Ambrisentan Viatris (previously Ambrisentan Mylan)

Ambrisentan Viatris is a medicine that is used alone or combined with other medicines to treat adults with pulmonary arterial hypertension (PAH). PAH is abnormally high blood pressure in the arteries of the lungs. Ambrisentan Viatris is used in patients with class II or III disease. The ‘class’ reflects the severity of the disease: ‘class II’ involves slight limitation of physical activity and ‘class III’ involves marked limitation of physical activity. Ambrisentan Viatris is effective in PAH with no identified cause and in PAH caused by connective tissue disease. Ambrisentan Viatris contains the active substance ambrisentan and is a ‘generic medicine’. This means that Ambrisentan Viatris contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Volibris. For more information on generic medicines, see the question\-and\-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf).